Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmune Bio Inc (NQ: INMB ) 6.130 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 6.130 Bid (Size) 5.800 (2) Ask (Size) 6.250 (1) Prev. Close 6.130 Today's Range 6.130 - 6.130 52wk Range 4.780 - 14.74 Shares Outstanding 17,703,692 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB October 28, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination October 24, 2024 From INmune Bio, Inc. Via GlobeNewswire Performance YTD -45.37% -45.37% 1 Month +19.26% +19.26% 3 Month -13.78% -13.78% 6 Month -38.21% -38.21% 1 Year -16.60% -16.60% More News Read More INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 October 24, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit October 11, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio: Q4 Earnings Insights March 28, 2024 Via Benzinga INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease September 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort September 26, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints September 17, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Announces $13.0 Million Registered Direct Offering September 13, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference September 03, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients July 29, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 July 25, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer July 23, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial June 27, 2024 From INmune Bio, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga INmune Bio Inc. to Join Russell 3000® Index May 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 May 07, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years April 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer April 29, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 25, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay April 23, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 April 08, 2024 From INmune Bio, Inc. Via GlobeNewswire INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 March 28, 2024 Via InvestorPlace INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering April 22, 2024 From INmune Bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
